Published mark
ARROWHEAD PHARMACEUTICALS, INC.
NASDAQ: ARWR. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:02360f2d-a681-4f24-b6c0-f5382664fcde
- SEC CIK
- 0000879407
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 21, 2026
- Newest evidence
- May 3, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Christopher AnzaloneSince Jan 27, 2026
- Chair
- Not published
- Independent
- 5 / 66 directors published
- Published claims
- 293 distinct sources
- Evidence records
- 80 pinned
- Source conflicts
- 0None open
Built from 3 distinct sources and 8 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
CEO CHANGED
Christopher Anzalone executive of ARROWHEAD PHARMACEUTICALS, INC., effective 2026-01-27.
EffectiveEffective Jan 27, 2026E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Chief Executive Officer, President, Director and Board Chair | Christopher Anzalone | Jan 2026 | current | Source reportedE3 |
| Chief Financial Officer | Daniel Apel | Jan 2026 | current | Source reportedE4 |
| Chief Medical Officer | James Hamilton | Jan 2026 | current | Source reportedE5 |
| Chief Operating Officer | Patrick C. O'Brien | Jan 2026 | current | Source reportedE6 |
| Senior Vice President, Investor Relations and Corporate Communications | Vincent Anzalone | Not captured | unknown | Source reportedE7 |
Board of directors
Evidence6 directors published. 5 of 6 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Adeoye Olukotun | Independent | 2020 | Nominating and Governance | Source reportedE2 |
| Christopher Anzalone, PhD | Not independent | 2007 | None published | Source reportedE2 |
| Hongbo Lu, PhD | Independent | 2024 | CompensationCompensation; Nominating and GovernanceNominating and Governance | Source reportedE2 |
| Mauro Ferrari, PhD | Independent | 2010 | AuditAudit; Nominating and GovernanceNominating and Governance | Source reportedE2 |
| Victoria Vakiener | Independent | 2022 | AuditAudit; Nominating and Governance · ChairNominating and Governance, chair | Source reportedE2 |
| William Waddill | Independent | 2018 | Audit, chairAudit · Chair; Compensation; Nominating and GovernanceCompensationNominating and Governance | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | William Waddill | William Waddill, Mauro Ferrari, PhD, Victoria Vakiener | Not described in the published record |
| Audit · Chair; Compensation; Nominating and Governance | Not published | William Waddill | Not described in the published record |
| Audit; Nominating and Governance | Not published | Mauro Ferrari, PhD | Not described in the published record |
| Audit; Nominating and Governance · Chair | Not published | Victoria Vakiener | Not described in the published record |
| Compensation | Not published | Hongbo Lu, PhD, William Waddill | Not described in the published record |
| Compensation; Nominating and Governance | Not published | Hongbo Lu, PhD | Not described in the published record |
| Nominating and Governance | Victoria Vakiener | Victoria Vakiener, Adeoye Olukotun, Hongbo Lu, PhD, Mauro Ferrari, PhD, William Waddill | Not described in the published record |
Committee RecordAudit: Chair William Waddill; Members William Waddill (Chair); Mauro Ferrari, PhD; Victoria Vakiener
Committee AppointmentWilliam Waddill: chair, Audit
Committee AppointmentMauro Ferrari, PhD: member, Audit
Committee AppointmentVictoria Vakiener: member, Audit
Committee RecordCompensation: Chair not stated; Members Hongbo Lu, PhD; William Waddill
Committee AppointmentHongbo Lu, PhD: member, Compensation
Committee AppointmentWilliam Waddill: member, Compensation
Committee RecordNominating and Governance: Chair Victoria Vakiener; Members Victoria Vakiener (Chair); Adeoye Olukotun; Hongbo Lu, PhD; Mauro Ferrari, PhD; William Waddill
Committee AppointmentVictoria Vakiener: chair, Nominating and Governance
Committee AppointmentAdeoye Olukotun: member, Nominating and Governance
Committee AppointmentHongbo Lu, PhD: member, Nominating and Governance
Committee AppointmentMauro Ferrari, PhD: member, Nominating and Governance
Committee AppointmentWilliam Waddill: member, Nominating and Governance
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerChristopher Anzalone, Chief Executive Officer, President, Director and Board Chair, from Jan 27, 2026
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingARWR (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 21, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameARROWHEAD PHARMACEUTICALS, INC.
Entity StatusPublic listing published
Published FactUS
Published FactHealthcare
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Christopher AnzaloneChief Executive Officer, President, Director and Board Chaircompany:02360f2d-a681-4f24-b6c0-f5382664fcde:leadership_role:12
- Daniel ApelChief Financial Officercompany:02360f2d-a681-4f24-b6c0-f5382664fcde:leadership_role:13
- James HamiltonChief Medical Officercompany:02360f2d-a681-4f24-b6c0-f5382664fcde:leadership_role:14
- Patrick C. O'BrienChief Operating Officercompany:02360f2d-a681-4f24-b6c0-f5382664fcde:leadership_role:15
- Vincent AnzaloneSenior Vice President, Investor Relations and Corporate Communicationscompany:02360f2d-a681-4f24-b6c0-f5382664fcde:leadership_role:16
- Adeoye OlukotunDirectorcompany:02360f2d-a681-4f24-b6c0-f5382664fcde:leadership_role:6
- Christopher Anzalone, PhDDirectorcompany:02360f2d-a681-4f24-b6c0-f5382664fcde:leadership_role:7
- Hongbo Lu, PhDDirectorcompany:02360f2d-a681-4f24-b6c0-f5382664fcde:leadership_role:8
- Mauro Ferrari, PhDDirectorcompany:02360f2d-a681-4f24-b6c0-f5382664fcde:leadership_role:9
- Victoria VakienerDirectorcompany:02360f2d-a681-4f24-b6c0-f5382664fcde:leadership_role:10
- William WaddillDirectorcompany:02360f2d-a681-4f24-b6c0-f5382664fcde:leadership_role:11
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 8 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 21, 2026. Cited by 5 Claims.
- E2sec proxy. Published Jan 27, 2026. Retrieved Apr 24, 2026. Cited by 6 Claims.
- E3sec filing. Published Jan 27, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E4sec filing. Published Jan 27, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E5sec filing. Published Jan 27, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E6sec filing. Published Jan 27, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E7ARWR executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E8board_seats. board seats. Cited by 13 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 21, 2026- Christopher Anzalone executive of ARROWHEAD PHARMACEUTICALS, INC., effective 2026-01-27.
- Daniel Apel executive of ARROWHEAD PHARMACEUTICALS, INC., effective 2026-01-27.
- James Hamilton executive of ARROWHEAD PHARMACEUTICALS, INC., effective 2026-01-27.
- Patrick C. O'Brien executive of ARROWHEAD PHARMACEUTICALS, INC., effective 2026-01-27.
- Hongbo Lu, PhD seat on ARROWHEAD PHARMACEUTICALS, INC., effective 2024-01-01.
- Compensation; Nominating and Governance committee of ARROWHEAD PHARMACEUTICALS, INC., effective 2024-01-01.
- Hongbo Lu, PhD member of Compensation; Nominating and Governance, effective 2024-01-01.
- Victoria Vakiener seat on ARROWHEAD PHARMACEUTICALS, INC., effective 2022-01-01.
- Audit; Nominating and Governance · Chair committee of ARROWHEAD PHARMACEUTICALS, INC., effective 2022-01-01.
- Victoria Vakiener member of Audit; Nominating and Governance · Chair, effective 2022-01-01.
- Adeoye Olukotun seat on ARROWHEAD PHARMACEUTICALS, INC., effective 2020-01-01.
- Adeoye Olukotun member of Nominating and Governance, effective 2020-01-01.
- William Waddill seat on ARROWHEAD PHARMACEUTICALS, INC., effective 2018-01-01.
- Audit · Chair; Compensation; Nominating and Governance committee of ARROWHEAD PHARMACEUTICALS, INC., effective 2018-01-01.
- William Waddill member of Audit · Chair; Compensation; Nominating and Governance, effective 2018-01-01.
- Mauro Ferrari, PhD seat on ARROWHEAD PHARMACEUTICALS, INC., effective 2010-01-01.
- Audit; Nominating and Governance committee of ARROWHEAD PHARMACEUTICALS, INC., effective 2010-01-01.
- Mauro Ferrari, PhD member of Audit; Nominating and Governance, effective 2010-01-01.
- Christopher Anzalone, PhD seat on ARROWHEAD PHARMACEUTICALS, INC., effective 2007-01-01.